Synthesis of indoline-thiazolidinone hybrids with antibacterial and antifungal activities

Y. T. Konechnyi1, A. V. Lozynskyi1, V. Ya. Horishny1, R. T. Konechna2, R. B. Vynnytska3, O. P. Korniychuk1, R. B. Lesyk1,4*

1 Danylo Halytsky Lviv National Medical University
69, Pekarska Str., Lviv, Ukraine, 79010
2 Lviv Polytechnic National University
12, S. Bandery Str., Lviv, Ukraine, 79013
3 Ivano-Frankivsk National Medical University
2, Halytska Str., Ivano-Frankivsk, Ukraine, 76018
4 University of Information Technology and Management in Rzeszow
2, Sucharskiego Str., Rzeszow, Poland, 35-225
dr_r_lesyk@org.lviv.net, roman.lesyk@gmail.com

Aim. Based of the Knoevenagel condensation reaction the synthesis of new rhodanine-indoline hybrid molecules for screening antibacterial and antifungal activities was accomplished. Methods. Organic synthesis, NMR spectroscopy, pharmacological screening. Results. The reaction between rhodanine-3-propanoic/ethanesulfonic acids and indolecarbaldehydes in the acetic acid provided series of 5-indolylmethylenerhodanine-3-carboxylic/sulfonic acid derivatives. Based on the esterification reaction with methanol in the presence of sulfuric acid, 5-indolylmethylenerhodanine-3-propanic acid was transformed into appropriate ester for further evaluation of antimicrobial activity. The antimicrobial activity screening allowed the identification of compounds with significant effect against Escherichia coli, Staphylococcus lentus and Candida albicans with MIC/MBC/MFC values in the range of 25-50 μg/mL. Conclusions. The synthesized 5-indolylmethylerhodanine-3-carboxylic/sulfonic acid derivatives are a convenient platform for the development of new highly active and low-toxic agents as potential drug-like molecules with antimicrobial activity.

Keywords: synthesis, 2-thioxo-4-thiazolidinone, indolecarbaldehydes, spectral data, antimicrobial activity.
Introduction

In the era of rapidly growing number of patients suffering from various infectious diseases, the searching for novel compounds with antibiotic activity is one of the global challenges in overcoming antimicrobial resistance [1]. In this context, prominent interest belongs to heterocyclic compounds, which are one of the most valuable sources of novel chemical entities with diverse biological activity due to their unique ability to mimic the structure of peptides and to bind reversibly to diverse biotargets [2]. Among the design strategies in drug discovery, considerable interest has been paid to thiazole-based heterocycles [3–5]. Thiazole/thiazolidinone derivatives constitute an important class of therapeutic agents in medicinal chemistry including antitrypanosomal [6], antiviral [7, 8], anticancer [9–11], antioxidant [12, 13], anti-inflammatory [14–16] activities and also display a pivotal role as antimicrobial and antifungal agents [17, 18]. Thus, a thiazole ring is present in several drugs, such as penicillin, monobactam, sulfathiazole, thiabendazole and nizatidine, making this heterocyclic fragment ideal for construction more potent and safer drug candidates, especially in the therapy of infectious diseases (Fig. 1). The antimicrobial activity evaluation is also actual and promising for thiazole-based compounds. Thus, among thiazolidinones, especially rhodanines have been identified several lactamases [19], Sortase A (SrtA) [20], Peptide deformylase [21], Protein mannosyl transferase 1 [22], UDP-galactopyranose mutase (UGM) [22], UDP-N-acetylmuramate/L-alanine ligase (MurC) [23] and Dolichophosphate mannose [24] synthase inhibitors.

It was envisaged, that the combination of thiazolidinone with other pharmacophores, especially indole fragment, would generate molecular templates with new pharmacological profile and lower toxicity [25]. Thus, among indole-based derivatives a set of potent plant hormones [26], essential amino acids [27], neurotransmitters [27], as well as a large number of commercial drugs and biologically ac-
tive molecules have been identified [28–30]. In continuation of this theme, we designed and synthesized new non condensed heterocyclic compounds containing 4-oxo-2-thioxothiazolidine (rhodanine), and pharmacologically attractive indole moieties (Fig. 2). The evaluation of their antimicrobial and antifungal activity in vitro against several reference and clinical strains was carried out.

Materials and Methods

Chemistry

The starting rhodanine-3-propanoic/ethanesulfonic acids 1,2 were obtained according to the known synthetic methods [17,31].

Melting points were measured in open capillary tubes and were uncorrected. The elemental analyses were performed using the Perkin–Elmer 2400 CHN analyzer. The analyses indicated by the symbols of the elements or functions were within ±0.4 % of the theoretical values. The $^1$H and $^{13}$C NMR spectra were recorded on Varian Gemini ($^1$H at 400 and $^{13}$C at 100 MHz) instrument in DMSO-d$_6$ using tetramethylsilane as an internal standard. Chemical shifts are reported in ppm units with use of δ scale. Mass spectra were obtained using electrospray (ES) ionization techniques on an Agilent 1100 Series LCMS.

**General procedure for the synthesis of 5-indolylmethylene rhodanine-3-propanoic/ethanesulfonic acids (3, 5, 6).** A mixture of rhodanine-3-propanoic/ethanesulfonic acid (5 mmol), sodium acetate (5 mmol), and appropriate indolecarbaldehyde (5.5 mmol) was refluxed for 2 h in 10 mL of acetic acid. A solid product that precipitated out was filtered, dried, and recrystallized from acetic acid (10–15 mL).

3-[5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-propanoic acid (3). Yield 96 %, mp 256-257 ºC (AcOH). $^1$H NMR (400 MHz, DMSO-d$_6$): δ 2.63 (t, 2H, $J = 7.8$ Hz, CH$_2$), 4.24 (t, 2H, $J = 7.8$ Hz, CH$_2$), 7.20-7.29 (m, 2H, arom.), 7.51 (d, 1H, $J = 7.8$ Hz, arom.), 7.89 (s, 1H, =CH), 12.38 (s, 1Н, NH).

$^{13}$C NMR (100 MHz, DMSO-d$_6$): δ 42.9, 45.5, 111.3, 113.5, 114.7, 118.9, 122.1, 123.1, 125.4, 126.7, 130.3, 136.9, 166.7, 191.3. ESI-MS m/z 334 (M+H)$^+$. Anal. Calcd for
C_{15}H_{13}N_{2}O_{3}S_{2}: C, 54.04; H, 3.93; N, 8.40. Found: C, 54.08; H, 3.85; N, 8.51.

2-[5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-ethanesulfonic acid (5). Yield 71 %, mp > 260ºC (AcOH). \(^1\)H NMR (400 MHz, DMSO-d\(_6\)): \(\delta\) 2.54 (t, 2H, \(J = 7.6\) Hz, CH\(_2\)), 4.27 (t, 2H, \(J = 7.5\) Hz, CH\(_2\)), 7.20-7.29 (m, 2H, arom.), 7.51 (d, 1H, \(J = 7.8\) Hz, arom.), 7.91 (s, 1H, arom.), 7.96 (d, 1H, \(J = 7.9\) Hz, arom.), 8.09 (s, 1H, =CH), 12.38 (s, 1H, NH). \(^13\)C NMR (100 MHz, DMSO-d\(_6\)): \(\delta\) 30.7, 51.6, 110.0, 112.5, 114.2, 118.4, 121.5, 123.3, 126.3, 126.7, 130.6, 136.3, 166.3, 170.6, 192.1. ESI-MS m/z 369 (M+H)+. Anal. Calcd for C\(_{14}\)H\(_{12}\)N\(_2\)O\(_4\)S\(_3\): C, 45.64; H, 3.28; N, 7.60. Found: C, 45.58; H, 3.22; N, 7.54.

3-[5-(1H-Indol-6-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-propanoic acid (6). Yield 74 %, mp > 260ºC (AcOH). \(^1\)H NMR (400 MHz, DMSO-d\(_6\)): \(\delta\) 2.55 (s, 3H, CH\(_3\)), 2.77 (t, 2H, \(J = 7.0\) Hz, CH\(_2\)), 4.27 (t, 2H, \(J = 7.0\) Hz, CH\(_2\)), 6.54 (s, 1H, arom.), 7.27 (d, 1H, \(J = 7.7\) Hz, arom.), 7.59 (m, 1H, arom.), 7.70 (d, 1H, \(J = 7.6\) Hz, arom.), 7.76 (m, 1H, arom.), 7.93 (s, 1H, =CH), 11.46 (s, 1H, NH). \(^13\)C NMR (100 MHz, DMSO-d\(_6\)): \(\delta\) 30.8, 40.4, 101.9, 115.2, 118.1, 121.0, 121.6, 125.6, 129.8, 130.1, 135.6, 136.0, 166.7, 171.7, 193.1. ESI-MS m/z 333 (M+H)+. Anal. Calcd for C\(_{15}\)H\(_{14}\)N\(_2\)O\(_3\)S\(_2\): C, 55.47; H, 4.07; N, 8.09. Found: C, 55.38; H, 4.12; N, 8.14.

**Pharmacology**

**Antimicrobial and antifungal activities in vitro (agar diffusion method)**

The antimicrobial activity of the synthesized compounds was studied by the method of diffusion into agar. Aliquots (50 μL) of 0.1 % tested compound solution in the mixture of EtOH : DMSO : water (2:1:1) were placed into wells in agar in Petri dishes with test microbes. The antimicrobial activity was evaluated by measuring the diameter of the zone of inhibition of microbial growth. The plates were incubated for 24 h at 37 ºC. The inhibition zone that appeared after 24 h around the well in each plate was measured in mm. Experiments were in triplicates and standard deviation was calculated. All compounds were tested against six Gram-negative (reference strains *Pseudomonas aeruginosa* (ATCC 27853 (F-51)), *Escherichia coli* (ATCC 25922); clinical multi-drug resistant strains (MDR) *Pseudomonas aeruginosa*, *Escherichia coli*; rarely found clinical strains *Raoultella terrigena* and *Brevundimonas ve-
Synthesis of indoline-thiazolidinone hybrids with antibacterial and antifungal activities

sicularis), five Gram-positive (reference strains Staphylococcus aureus (ATCC 25923 (F-49)), Bacillus licheniformis (BKIM-7038); clinical MDR strain Staphylococcus aureus; rarely found clinical strains Staphylococcus lentus and Staphylococcus lugnuniensis) bacterial strains, according to the literature protocol [32]. Clinical strains were isolated from patient with nosocomial infections. In vitro antibacterial activity was determined by using Mueller Hinton Agar plates. The antifungal screening of all compounds was carried out against reference strain of yeast Candida albicans (ATCC 885–653); clinical MDR strains Candida dubliniensis, Candida albicans; and reference strain of mold Aspergillus niger, s according to the literature protocol [33, 34]. In vitro antifungal activity was determined by using Sabouraud Agar plates. All results were compared with those of the DMSO.

The MICs of the compound assays were carried out using the microdilution susceptibility method. The microorganism suspensions were inoculated to the corresponding wells. The plates were incubated at 36 °C for 18 h for bacteria and fungi, respectively. The minimum inhibitory concentrations of the compounds were recorded as the lowest concentration of each compound in the tubes with no turbidity (i.e. no growth) of inoculated bacteria/fungi.

**Acute toxicity**

The experiments were conducted on white male mice weighing 23–25 g. Compounds were dissolved in saline solution (0.9 % NaCl) with 1-2 drops of Polysorbate 80 (Tween-80®). After dissolution they were administered to mice by the oral route. The LD$_{50}$ was evaluated for 4 or 5 different doses each on 6 animals and calculated by the Litchfield-Wilcoxon method [35, 36].

**Results and Discussion**

**Chemistry**

The general methods for synthesis of target indoline substituted rhodanines are depicted in Scheme 1. The starting rhodanine-3-propanoic/ethanesulfonic acids were synthesized per the procedure reported previously [17, 31]. The target 5-indolylmethylen-3-substituted rhodanines were obtained by the Knoevenagel reaction in the medium of acetic acid in the presence of sodium acetate. Additionally, 5-indolymethylenrhodanine-3-propanoic acid 3 was transformed into corresponding ester 4 via heating with alcohols in the presence of an acid as a catalyst. The structures of synthesized compounds were elucidated by the spectral data (1H and 13C NMR). The 1H NMR spectra of compounds (3-6) CH$_2$ protons of the alkyl fragment in position N-3 appear as a triplet at δ 2.63–2.77 and 4.24–4.30 ppm, respectively. The chemical shift of the methylene group (=CH) of synthesized 5-indolidenederivatives is insignificantly displaced in the weak magnetic field, δ 7.93–8.09 ppm, and clearly indicated that only Z-isomers were obtained in the Knoevenagel reaction of rhodanines with indole-carbaldehydes. The signals of NH group of indole fragment appeared as single-proton singlets displaced in the weak magnetic field at δ 11.46–12.41 ppm. In the 13C NMR spectra the characteristic signals of (thio)carbonyl carbons at δ ~166.3–193.1 ppm and the signals of methylene group (130.3–135.6 ppm) are observed.
**Biological activity**

The synthesized compounds were screened for their *in vitro* antibacterial and antifungal activities using the agar diffusion method [32]. A total of 15 microorganisms which consisted of eleven bacteria, three yeasts and one mold fungi were tested. Clinical and rarely found clinical strains were multidrug resistant [37] and isolated from patient with health-care-associated infections. All the synthesized compounds exhibited varying degree of inhibitory effect on the growth of different tested strains at a dose of 50 μg per well (Table 1 and Fig. 3). The synthesized compounds showed different mean zone of inhibition in the range of 00-19.4 mm against tested microorganisms. DMSO was used as control. Compounds 3 and 4 show good antifungal activity against *Candida albicans, Candida dubliniensis, Aspergillus niger* and did not possess significant antibacterial activity. Compound 5 showed the highest activity against *Escherichia coli, Bacillus licheniformis, Staphylococcus aureus, Staphylococcus lugnuniensis*. Compound 6 displayed moderate activity against *Raoulletella terrigena*. No significant antifungal activity was observed for compounds 5 and 6.

The minimum inhibitory concentrations (MIC) for the most active compounds 3-6 against several microorganisms were calculated using the broth microdilution method (Resazurin Reduction-Based Assay) [33,34] (Table 2). The tested compounds exhibited the inhibitory activity against clinical strains *Escherichia coli, Staphylococcus lentus* and *Candida albicans* with MIC 00-50 μg/mL. Two compounds showed a moderate activity (dilution 1:4) against *Candida albicans* (compound 3), *Escherichia coli* and *Staphylococcus lentus* (compound 5) with MIC 25.0 μg/mL respectively. Compound 4 exhibited at the same dilution a slightly lower
inhibitory activity with MIC 50 μg/mL against *Candida albicans*. Compound 6 was inactive against tested microorganisms. Interestingly, the tested compounds at dilution 1:1 possessed a slight inhibitory activity with MIC 50.0 μg/mL.

The SAR analysis showed that the antibacterial effect of compounds 3-6 depends on the substituents at C-5 and N-3 positions of 2-thioxo-1,3-thiazolidin-4-one (rhodanine) core. The 5-enerhodanine-3-propanoic acid 3 with indol-3-ylmethylene fragment in the mol-

### Table 1. Antibacterial and antifungal activities of the synthesized compounds.

| №   | Type of species               | Species of bacteria and fungi                  | Diameter of inhibitory zones (mm ± SE)     |
|-----|-------------------------------|------------------------------------------------|--------------------------------------------|
|     |                               |                                                | Compd 3 | Compd 4 | Compd 5 | Compd 6 | DMSO |
| 1   | Gram-negative bacteria        | *Pseudomonas aeruginosa (ATCC 27853 (F-51))*    | 7.2 ± 0.3 | 00      | 8.5 ± 0.5 | 00      | 00   |
| 2   |                               | *Escherichia coli (ATCC 25922)*                | 00       | 00      | 15.2 ± 0.4 | 00      | 00   |
| 3   | clinical strains              | *Pseudomonas aeruginosa № 7 (n=4)*            | 7.0 ± 0.3 | 00      | 7.5 ± 0.5 | 00      | 00   |
| 4   |                               | *Escherichia coli № 5 (n=4)*                  | 7.0 ± 0.2 | 7.0 ± 0.2 | 15.4 ± 0.6 | 7.0 ± 0.2 | 7.0 ± 0.2 |
| 5   | rarely found clinical strains | *Raoultella terrigena № 1 (n=4)*             | 00       | 00      | 6.6 ± 0.2 | 8.0 ± 0.3 | 00   |
| 6   |                               | *Brevundimonas vesicularis № 111 (n=4)*       | 00       | 00      | 00       | 00      | 00   |
| 7   | Gram-positive bacteria        | *Staphylococcus aureus (ATCC 25923 (F-49))*   | 7.0 ± 0.2 | 7.0 ± 0.2 | 6.8 ± 0.4 | 6.8 ± 0.4 | 6.8 ± 0.4 |
| 8   |                               | *Bacillus licheniformis (BKIM-7038)*          | 7.0 ± 0.3 | 00      | 9.5 ± 0.5 | 00      | 00   |
| 9   | clinical strains              | *Staphylococcus aureus 120 (n=4)*              | 00       | 00      | 12.2 ± 0.4 | 00      | 00   |
| 10  | rarely found clinical strains | *Staphylococcus lentus № 21 (n=4)*            | 00       | 00      | 10.3 ± 0.5 | 00      | 00   |
| 11  |                               | *Staphylococcus lugnumiensis 142*             | 00       | 00      | 9.5 ± 0.5 | 00      | 00   |
| 12  | Fungi                         | *Candida. albicans (ATCC 885-653)*            | 19.4 ± 0.5 | 15.4 ± 0.6 | 7.2 ± 0.2 | 7.2 ± 0.2 | 7.2 ± 0.2 |
| 13  | clinical strains of yeast    | *Candida dubliniensis № 67 (n=4)*            | 14.5 ± 0.6 | 10.5 ± 0.6 | 00      | 00      | 00   |
| 14  |                               | *Candida albicans № 60 (n=4)*                 | 12.5 ± 0.6 | 11.5 ± 0.6 | 00      | 00      | 00   |
| 15  | reference strain of mold     | *Aspergillus niger № 162*                     | 15.5 ± 0.5 | 14.5 ± 0.5 | 00      | 00      | 00   |

00: no activity; diameter of zone of inhibition (mm) including the well diameter of 6 mm; data are presented as mean ±SD (n = 3)
ecule displayed the equivalent antimicrobial activity to its ester 4. The derivative 5 with ethanesulfonic acids substituent of rhodanine core at N-3 and indol-3-ylmethylene fragment at C-5 was the most active and demonstrated a good effect against all tested bacteria with

| №  | Type of species | Species of bacteria and fungi | Minimum Inhibitory (MIC) and Bactericidal/Fungicidal Concentration (MBC/MFC) | Compd 3 | Compd 4 | Compd 5 | Compd 6 |
|----|----------------|-------------------------------|------------------------------------------------------------------------------|--------|--------|--------|--------|
|    |                |                               | Minimum Inhibitory (MIC) (µg/mL) | MIC (µg/mL) | MIC (µg/mL) | MIC (µg/mL) | MIC (µg/mL) |
|    |                |                               | MBC/MFC (µg/mL) | MBC/MFC (µg/mL) | MBC/MFC (µg/mL) | MBC/MFC (µg/mL) | MBC/MFC (µg/mL) |
| 1  | Gram-negative bacteria | Escherichia coli №5 | 0 | 0 | 0 | 0 | 1:4 (25 µg/mL) | 1:1 (50 µg/mL) | 0 | 0 |
| 2  | Gram-positive bacteria | Staphylococcus lentus № 21 | 0 | 0 | 0 | 0 | (1:4 25 µg/mL) | (1:1 50 µg/mL) | 0 | 0 |
| 3  | Fungi | Candida albicans №60 | 1:4 (25 µg/mL) | 1:1 (50 µg/mL) | 1:1 (50 µg/mL) | 1:1 (50 µg/mL) | 0 | 0 | 0 | 0 |

Fig. 3. Comparison of antibacterial and antifungal activities of compounds 3-6.
MIC 25 µg/mL. The introduction of indol-6-ylmethylene fragment at C-5 position of rhodanine-3-propanoic acid provides the loss of antibacterial and antifungal activities.

For the synthesized compounds, the acute toxicity in mice was studied and their medium lethal doses (LD₅₀ value) were determined. The stock solutions of the compounds used in this study were prepared immediately before usage and increasing amounts of substances (100–1000 mg/kg) were injected intraperitoneally. The LD₅₀ values were calculated according to Litchfield and Wilcoxon. The synthesized compounds showed low acute toxicity in mice with the LD₅₀ values within the range of 300–350 mg/kg (Table 3).

Table 3. Acute toxicity of the target compounds.

| Compound | LD₅₀, mg/kg |
|----------|------------|
| 3        | 960.0 ± 64.5 |
| 4        | 1005.0 ± 67.0 |
| 5        | 1050.6 ± 67.5 |
| 6        | 900.0 ± 57.0 |

Conclusions

The new 5-indolylmethylnerhodanine-3-propanoic/ethanesulfonic acids derivatives 3–6 were synthesized via the Knoevenagel reaction from appropriate rhodanine-3-propanoic/ethanesulfonic acids and indolecarbaldehydes. The antimicrobial screening of synthesized compounds against reference and clinical strains bacteria and fungi was performed. It was found that some derivatives have potential antimicrobial activity against Escherichia coli, Staphylococcus lentus and Candida albicans and are attractive as a novel template for the design of new synthetic antibacterial/antifungal agents.

REFERENCES

1. Mendelson M, Matsoso MP. The World Health Organization global action plan for antimicrobial resistance. S Afr Med J. 2015; 105(5):325.
2. Piggott AM, Karuso P. Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb Chem High Throughput Screen. 2004; 7(7):607–630.
3. Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin Drug Discov. 2017; 12(12):1233–52.
4. Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK. 4-Thiazolidinones: the advances continue…. Eur J Med Chem. 2014; 72:52–77.
5. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem. 2012; 55(2):743–753.
6. Kryshchyshyn A, Kaminskyy D, Grellier P, Lesyk R. Trends in research of antitrypanosomal agents among synthetic heterocycles. Eur J Med Chem. 2009; 44(9):3746–3753.
7. El-Sabbagh OI, Baraka MM, Ibrahim SM, Pannecoque C, Andrei G, Snoeck R, Balzarini J, Rashad AA. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem. 2005; 40(7):743–753.
8. de Souza MV. Synthesis and biological activity of natural thiazoles: An important class of heterocyclic compounds. J Sulfur Chem. 2005; 26(4-5):429–449.
9. Wang S, Zhao Y, Zhu W, Liu Y, Guo K, Gong P. Synthesis and Anticancer Activity of Indolin-2-one Derivatives Bearing the 4-Thiazolidinone Moiety. Arch Pharm. 2012; 345(1):73–80.
10. Verma A, Saraf SK. 4-Thiazolidinone-A biologically active scaffold. Eur J Med Chem. 2008; 43(5):897–905.
11. Lozynskyi A, Zimenkovsky B, Radko L, Stypula-Trebas S, Roman O, Gzella AK, Lesyk R. Synthesis and cytotoxicity of new thiazolo[4,5-b]pyridine-2(3H)-one derivatives based on α,β-unsaturated ketones and α-ketoacids. Chem Pap. 2018; 72(3):669–681.
12. Lozynskyi A, Zasidko V, Atamanyuk D, Kaminsky D, Derkach H, Karpenko O, Ogurtsov V, Kutsyk R, Lesyk R. Synthesis, antioxidant and antimicrobial activities of novel thiopyran[2,3-d]thiazoles based on arylacrylic acids. Mol Divers. 2017; 21(2):427–436.

13. Geronikaki AA, Pitta EP, Liaras KS. Thiazoles and thiazolidinones as antioxidants. Curr Med Chem. 2013; 20(36):4460–4480.

14. Fomenko I, Bondarchuk T, Emelyanenko V, Denysenko N, Pavlo S, Ilkiv I, Lesyk R, Sklyarov A. Changes of nitric oxide system and lipid peroxidation parameters in the digestive system of rats under conditions of acute stress, and use of nonsteroidal anti-inflammatory drugs. Curr Issues Pharm Med. Sci. 2015; 28(1):37–41.

15. Ilkiv I, Lesyk R, Sklyarov O. Evaluation of novel 4-thiazolidinone-based derivatives as possible cytoprotective agents against stress model in rats. J Appl Pharm Sci. 2017; 7:199–203.

16. Ottana R, Maccari R, Barreca ML, Bruno G, Rotondo A, Rossi A, Chiricosta G, Di Paola R, Saubelin L, Cuzzocrea S, Vigorita MG. 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents. Bioorg Chem. 2005; 13(13):4243–4252.

17. Horishny V, Kartsev V, Geronikaki A, Matiychuk V, Petrou A, Glamociija J, Ciric A, Sokovic M. 5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl) alkancarboxylic Acids as Antimicrobial Agents: Synthesis, Biological Evaluation, and Molecular Docking Studies. Molecules. 2020; 25(8):1964.

18. Vicini P, Geronikaki A, Anastasia K, Incerti M, Zani F. Synthesis and antimicrobial activity of novel 2-thiazoliylimino-5-arylidene-4-thiazolidinones. Bioorg Med Chem. 2006; 14(11):3859–3864.

19. Grant EB, Guiadeen D, Baum EZ, Foleno BD, Jin H, Montenegro DA, Nelson EA, Bush K, Hlata DJ. The synthesis and SAR of rhodanes as novel class C β-lactamase inhibitors. Bioorg Med Chem Lett. 2000; 10(19):2179–2182.

20. Suree N, Yi SW, Thieu W, Marohn M, Damoiseaux R, Chan A, Jung ME, Clubb RT. Discovery and structure–activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem Lett. 2009; 17(20):7174–7185.

21. Howard MH, Cenital Z, Gutteridge S, Hanna WS, Tao Y, Totrov M, Wittenbach VA, Zheng YJ. A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J Med Chem. 2004; 47(27):6669–6672.

22. Carlson EE, May JF, Kiessling LL. Chemical probes of UDP-galactopyranose mutase. Chem Biol. 2006; 13(8):825–837.

23. Sim MM, Ng SB, Buss AD, Crasta SC, Goh KL, Lee SK. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg Med Chem Lett. 2002; 12(4):697–699.

24. Smith TK, Young BL, Denton H, Hughes DL, Wagner GK. First small molecular inhibitors of t. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in african sleeping sickness. Bioorg Med Chem Lett. 2009; 19:1749–1752.

25. Havrylyuk D, Zimenkovsky B, Lesyk R. Synthesis, biological activity of thiazolidinones bearing indole moiety and isatin based hybrids. Mini-Rev Org Chem. 2015; 12(1):66–87.

26. Kende H, Zeevaart J. The five”Classical” plant hormones. Plant Cell. 1997; 9(7):1197–1210.

27. de Sa A, Fernando R, Barreiro EJ, Manssour Fraga CA. From nature to drug discovery: the indole scaffold as a ‘privileged structure’. Mini-Rev Org Chem. 2009; 9(7):782–93.

28. Chadha N, Silakari O. Indoles as therapeutics of interest in medicinal chemistry: Bird’s eye view. Eur J Med Chem. 2017; 134:159–84.

29. Ölgen S, Özkan S. A study of 3-substituted benzylidene-1,3-dihydro-indole derivatives as antimicrobial and antiviral agents. Z Naturforsch. C. 2009; 64(3-4):155–62.

30. Farag AA. Synthesis and antimicrobial activity of 5-(morpholinosulfonyl) isatin derivatives incorporating a thiazole moiety. Drug Res. 2015; 65(07):373–379.

31. Tejchman W, Korona-Gołowniak I, Malm A, Zylewski M, Suder P. Antibacterial properties of 5-substituted derivatives of rhodanine-3-carboxyalkyl acids. Med. Chem. Res. 2017; 26(6):1316–1324.

32. Matuschek E, Brown DF, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial
susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect. 2014; 20(4):O255–66.

33. Chowdhary A, Singh PK, Kathuria S, Hagen F, Meis JF. Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphoteracin B against molecularly identified Mucorales species. Antimicrob. Agents Chemother. 2015; 59(12):7882–7887.

34. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016; 6(2):71–79.

35. Litchfield JJ, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2):99–113.

36. Smith WG. Pharmacological screening tests. Prog Med Chem. 1961; 1:1–33.

37. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson Liljequist B, Paterson DL. Multidrug resistant, extensively drug resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3):268–81.